What are the treatment recommendations for relapsed or refractory FLT3-positive acute myeloid leukemia (AML)?

Updated: Dec 05, 2018
  • Author: Karen Seiter, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print
Answer

Answer

For relapsed or refractory FLT3-positive AML

  • Gilteritinib 120 mg PO once daily for at least 6 months for a clinical response or until disease progression or unacceptable toxicity

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!